Hundreds more people with suspected kidney cancer should have a biopsy to help confirm their diagnosis sooner and treat their disease more effectively, according to new draft guidelines from NICE.

Targeted immunotherapy found to significantly increase overall survival rates for people with an aggressive form of lung cancer has been recommended by NICE. People with an aggressive form of lung ...

Fertility clinics should not offer unproven treatments that don't help people have babies, our independent committee has recommended in draft guidance.

There are commercial access agreements for enfortumab vedotin and pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Pneumonia: diagnosis and management QS110 19 January 2016 2 September 2025 Pneumonia: diagnosis and management NG250 2 September 2025 2 September 2025 Suspected acute respiratory infection in over 16s ...

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal ...

Access to hybrid closed loop systems will be through a 5‑year phased roll out in line with NHS England's implementation plan. For enquiries about cost-effective pricing, contact Leigh.Carr@supplychain ...

This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z‑drugs and antidepressants in primary and secondary care. It does not ...

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults. Next review: More ...

NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with MET exon 14 skipping in adults. This is because Novartis Pharmaceuticals did not ...

This guideline has been updated and replaced by NICE's guideline on pneumonia in adults: diagnosis and management (NG250).

Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults. Next review: More evidence on elranatamab is being ...